论文部分内容阅读
近年来恶性黑素瘤发病率有明显上升趋势,其对单纯放疗及化疗均不敏感,它是一种免疫原性较高的肿瘤。目前用于恶性黑素瘤的生物治疗方法包括免疫治疗、基因治疗及抗血管生成治疗等,其中过继性免疫治疗的临床应用研究近年来得到快速发展,同时免疫调节性单克隆抗体药物以及针对BRAF基因V600E突变和C-KIT基因突变为靶点的临床研究最引人关注。这些研究为恶性黑素瘤的免疫及基因治疗提供了新思路,成为目前的研究热点。
In recent years, the incidence of malignant melanoma has a clear upward trend, which is not sensitive to radiotherapy alone and chemotherapy, it is a highly immunogenic tumor. At present, the biological treatment methods for malignant melanoma include immunotherapy, gene therapy and anti-angiogenesis therapy. The clinical application of adoptive immunotherapy has been rapidly developed in recent years. Meanwhile, immunomodulatory monoclonal antibody drugs as well as anti-BRAF The most notable clinical study of the V600E mutation and the C-KIT gene mutation as targets. These studies provide a new idea for the immune and gene therapy of malignant melanoma and become the current research hotspot.